Tumors with High CXCR4 Expression
Conditions
Interventions
Gold Standard:Pathological tissue CXCR4 expression level
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 75 years (inclusive), regardless of gender; (2) Clinically suspected or diagnosed with one of the following diseases, and planned or in need of whole-body evaluation of CXCR4 receptor status: 1) Department of Endocrinology/Urology: Patients clinically suspected of having primary hyperaldosteronism requiring diagnosis and subtyping (e.g., differentiation between adrenal adenoma and hyperplasia); or patients with Cushing's syndrome suspected of having cortisol-secreting adenoma, who should have completed surgical treatment. 2) Department of Hematology: Patients with newly diagnosed or relapsed/refractory hematologic malignancies such as multiple myeloma or lymphoma (e.g., mantle cell lymphoma, marginal zone lymphoma, etc.). 3) Department of Neurosurgery: Patients with suspected or diagnosed pituitary tumors. (3) The patient is informed and voluntarily signs a written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Pregnant or nursing women 2.A known history of severe allergies to [68Ga]Ga-Pentixafor or its analogues 3.Received chemotherapy, targeted therapy, radiotherapy, immunotherapy or participated in other radiopharmaceutical intervention clinical studies within 4 weeks before the first imaging 4.Suffering from any serious disease that is difficult to control (such as active severe infection, New York Heart Function Class III-IV heart failure, severe liver and kidney dysfunction, etc.) 5.Any circumstances that are inappropriate for PET/CT examination (such as claustrophobia, inability to lie flat for more than 30 minutes, etc.) 6.The investigator judges that there are other circumstances that are inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax; | — |
Secondary
| Measure | Time frame |
|---|---|
| SUVmean;Metabolic Tumor Volume; | — |
Countries
China
Contacts
Public ContactHua Pang
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed